Clinical Trials Directory

Trials / Conditions / TTR-mediated Amyloidosis

TTR-mediated Amyloidosis

8 registered clinical trials studyying TTR-mediated Amyloidosis.

StatusTrialSponsorPhase
CompletedA Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
NCT02292186
Alnylam PharmaceuticalsPhase 2
CompletedPhase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
NCT01981837
Alnylam PharmaceuticalsPhase 2
CompletedAPOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-
NCT01960348
Alnylam PharmaceuticalsPhase 3
CompletedThe Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients W
NCT01961921
Alnylam PharmaceuticalsPhase 2
CompletedA Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic
NCT01814839
Alnylam PharmaceuticalsPhase 1
CompletedSafety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis
NCT01617967
Alnylam PharmaceuticalsPhase 2
CompletedTrial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects
NCT01559077
Alnylam PharmaceuticalsPhase 1
Approved For MarketingExpanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
NCT02939820
Alnylam Pharmaceuticals—